Genetic Ablation of Smoothened in Tumor-Associated Fibroblasts Promotes Pancreatic Tumorigenesis by Pitarresi, Jason R.
1 
Department of Molecular and Cellular Biochemistry, College of Medicine, The Ohio State University, Columbus, 
OH, USA 
2 
Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA 
*The research summarized herein has been conducted collaboratively. The primary author would like to graciously 
acknowledge and thank Xin Liu, Maria C. Cuitiño, Sarah Woelke, Stefan Trela, Raleigh Kladney, Lianbo Yu, 
Jinghai Wu, and Michael C. Ostrowski for their scientific contributions. 






Pancreatic cancer remains an overwhelmingly fatal disease with less than 5% of patients 
surviving beyond 5 years, largely due to our lack of understanding of the complexity of the 
disease. Many recent reports have begun to highlight the potential role that stromal cells—
fibroblasts in particular—may have on pancreatic tumor cell biology and this report provides 
data that supports the theory of tumor-stroma co-evolution in pancreatic cancer. Here we use a 
novel mouse model to show that Smoothened (Smo) in the tumor-associated stroma suppresses 
pancreatic tumor initiation and development. We observed an increase in tumorigenesis events 
such as acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) 
lesions when Smo is conditionally deleted in pancreatic cancer associated fibroblasts (CAFs). To 
determine how Smo in fibroblasts is able to effect tumor progression, we harvested pancreatic 
CAFs from Smo-deleted and Smo-intact tumor bearing mice and performed microarray gene 
expression analysis. We found that Smo deleted CAFs had significantly altered the tumor 
suppressor PTEN, resulting in misregulated Phosphoinositide 3-kinase (PI3K) oncogenic 
pathway signaling. Thus, Smo ablation in pancreatic fibroblasts enhanced pancreatic tumor 
initiation primarily through loss of PTEN in fibroblasts. This report shows that deleting a gene in 
pancreatic fibroblasts causes a change in tumor-stroma co-evolution and that Smo is able to act 
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as a novel tumor suppressor in cancer associated fibroblasts to promote pancreatic 
carcinogenesis. 
Introduction 
Pancreatic cancer is an overwhelmingly fatal disease with approximately 95% of patients dying 
within 5 years of diagnosis [Siegel et al., 2013]. Moreover, our lack of knowledge in pancreatic 
cancer is evident in the fact that it has the least significant improvement in overall survival rate 
amongst all cancers over the last 35 years [Siegel et al., 2013]. Early studies on this disease 
focused on uncovering the genetics behind tumor formation, which led to the discovery of 
KRAS, CDKN4A, TP53, and SMAD4 mutations within tumor cells [Almoguera et al., 1998, 
Caldas et al., 1994, Redston et al., 1994, Hahn et al., 1996]. These studies were all performed in 
order to better understand the genetics behind Pancreatic Ductal Adenocarcinoma (PDAC), the 
most clinically prevalent form of pancreatic cancer. Recently, researchers have begun to study 
earlier events in pancreatic tumorigenesis and it has become apparent that PDAC originates from 
premalignant lesions termed Pancreatic Intraepithelial Neoplasms (PanIN) that arise from 
activating KRAS mutations in the epithelium [Hezel et al., 2006]. These efforts have also 
uncovered potential tumor initiating transformation events where pancreatic acinar epithelial 
cells trans-differentiate into ductal cells (termed acinar-to-ductal metaplasia, ADM) and then 
progress to PanIN [De La O et al., 2008]. Importantly, this transition from ADM to PanIN to 
PDAC is associated with a dramatic expansion of the pancreatic stroma, particularly in the 
fibroblast compartment. Thus far, the genetics of the tumor microenvironment during pancreatic 
tumor formation have been largely ignored. This report looks to further the understanding of the 
role that the pancreatic stroma plays in epithelial transformation using genetically engineered 
mouse models. 
The Hedgehog (HH) pathway is indispensable for normal development and often is 
inappropriately re-activated in many human cancers [Yauch et al., 2008 and Jiang et al. 2008]. 
HH ligands bind to the receptor Patched1 (PTCH1), releasing its’ repression of Smoothened 
(SMO), the key component of the signaling cascade. Molecular and genomic analysis of human 
pancreatic tumors indicate that Hedgehog signaling is one of the core signaling pathways 
contributing to tumor malignancy [Tian et al., 2009 and Jones et al., 2008]. A prevailing view is 
that HH signaling in pancreatic cancer occurs in a paracrine manner leading primarily to 
activation of the pathway in stromal fibroblasts [Tian et al., 2009 and Bailey et al., 2009]. 
Consistent with this view, the reduction in tumor load upon SMO inhibition obtained in a GEM 
PDAC model was interpreted to indicate that stromal SMO inhibition could be a potential anti-
tumor therapeutic [Oliver et al., 2009]. However, subsequent clinical trials based on these 
observations have failed in pancreatic cancer patients [Ruch et al., 2013]. More recently, ablation 
of Sonic Hedgehog (SHH) ligand in tumor cells or SHH co-receptors in fibroblasts was shown to 
decrease stromal activation and increase tumor cell growth [Rhim et al., 2014; Lee et al., 2014; 
Mathew et al., 2014]. These results bring into question the function of hedgehog signaling in the 
tumor stroma, and in particular in tumor fibroblasts, during pancreatic cancer progression. 






 (herein referred to as Smo
fl
), and Fsp-Cre alleles have all been 
previously described [Tuveson et al., 2006, Long et al., 2001, and Trimboli et al., 2008]. The use 
of animals was in compliance with federal and University Laboratory Animal Resources 
(ULAR) at The Ohio State University regulations and was conducted under the protocol 
(2007A0120) which was reviewed and approved by the Ohio State University Institutional 




 mice were sacrificed from 15-30 weeks after birth as indicated. At the time of 
euthanasia, total body weight and pancreas/tumor weight were documented. Pancreata, liver, and 
lung were removed and either frozen in OCT or fixed in formalin for 48-72 hours for subsequent 
histological processing by the Soild Tumor Pathology Core at OSU.  
Pancreatic Cancer Associated Fibroblast Isolation 
Mist1-Kras
G12D
 mice were euthanized and individual pancreata were removed and minced in 
5mg/ml Type II collagenase in PBS. After mincing, pancreata were dissociated by shaking at 225 
RPM at 37°C for 60 minutes. Cells were washed with complete Dulbecco's Modified Eagle 
Medium (DMEM, containing 10% FBS) and then pelleted by centrifugation at 200xg for 5 
minutes at 4°C. Cell pellets were resuspended in 5ml complete DMEM and allowed to gravity 
precipitate at room temperature for 10 minutes. After precipitation, top 3ml of solution was 
discarded and cellular pellet was resuspended in up to 5ml of complete DMEM, thus constituting 
one round of gravity precipitation. An additional round of gravity precipitation was conducted 
and the final cellular pellet was seeded. 24-hours post seeding media was replaced with complete 
DMEM. To further purify fibroblasts cultures, selective trypsonization was utilized where 0.25% 
trypsin was added to PBS-washed plated for 90 seconds and then fibroblasts were collected and 
re-seeded on a new plate. Fibroblast purity was confirmed by immunofluorescence as noted.  
Immunofluorescence and Histological Staining of Tissue Sections 
After removal from the body, tissue was immediately frozen in OCT or fixed in formalin for 48 
hours, transferred to 70% ethanol and then paraffin embedded. Frozen or embedded tissue was 
subsequently sectioned and mounted on glass slides for further analysis. Sections were processed 
with xylenes and ethanol prior to DAKO antigen retrieval in a streamer for 30 minutes. Sections 
were blocked with DAKO protein block and tissues were stained with anti- F4/80 (Invitrogen), -
vimentin (Cell Signaling), beta amylase (Cell Signaling), -cytokeratin 19 (Iowa Developmental 
Studies Hybridoma Bank), and -Ki67 (Abcam) as noted. Hematoxylin and eosin (H&E) and 
Masson’s Trichrome staining was performed by the Solid Tumor Pathology Core at OSU. 
Immunofluorescence Staining of Fibroblast Cultures 
Cells were grown on glass cover slips to 90% confluence and fixed using 4% PFA. Fixed cells 
were blocked using DAKO protein block and stained with anti-α smooth muscle actin (Abcam) 
and –cytokeratin 19 (Iowa Developmental Studies Hybridoma Bank) as noted. 
Western blotting 
Primary  pancreatic fibroblasts and were harvested by trypsinization and lysed in ice-cold RIPA 
lysis buffer, supplemented with 1mM PMSF, protease inhibitors (Amersham), and phosphatase 
inhibitor cocktails 1 and 2 (Sigma). Protein concentration was quantified using Bradford assay 
(Sigma). Samples were fractionated by SDS–PAGE and transferred onto nitrocellulose 
membranes (Millipore), using the BioRad electrophoresis system (BioRad). Membranes were 
blocked in 5% nonfat dry milk in TBS-Tween (150 mM NaCl, 5 mM Tris-HCL ,pH 7.4), and 
blotted with primary antibodies: rabbit polyclonal antibody against SMO (1:500), Pten (1:1000), 
p-Akt (1:1000), total Akt (1:1000) from Cell Signaling Technology. Horseradish peroxidase-
conjugated anti-mouse and anti-rabbit secondary antibodies, both used at 1:10000 dilution. 
Signal was developed with the ECL detection reagent (Amersham). 
RNA Isolation and Quantitative Real Time PCR 
RNA was isolated using Trizol reagent (Invitrogen), treated with DNase I (Ambion), and cDNA 
was generated using Superscript III Reverse Transcription (Invitrogen) as per the manufacturer’s 
specifications. Quantitative real time PCR was performed using primer specific Roche Universal 
Probe Library system on Applied Biosystems Step One Plus real time PCR systems. 
Gene Set Enrichment Analysis (GSEA) 
GSEA v2.0 was downloaded from the BROAD institute (http://www.broadinstitute.org/gsea) and 
used to determine molecular pathways that were misregulated upon deletion of Smo. Gene sets 
were obtained from Broad institute GSEA and ToppGene Suite databases. Statistical analysis 
was determined using 1,000 random permutations of each gene set to obtain a nominal P value 




 Mice Developed Dramatic Stromal Reaction 
Mist-Kras
G12D 
mice have been previously shown to develop mixed differentiated pancreatic 
carcinoma with the accompaniment of a rich stromal component, similar to human tumors 
[Tuveson et al., 2006]. We further characterized the Mist1-Kras
G12D
 mouse tumor model by 
performing a time-course analysis of the stromal reaction as the disease progresses. We 
monitored tumor histology on a bi-weekly basis and determined that 23 weeks of age 
consistently lead to increased collagen deposition in Mist1-Kras
G12D 
mice pancreata relative to 
wild type mice, as measured by Masson’s Trichrome staining (Figure 1A-B). Histologically, 23-
week old Mist1-Kras
G12D
 mice have developed PanIN and ADM lesions, but are still 
premalignant. Furthermore, we showed a dramatic increase in SMA+ fibroblasts and F4/80+ 
macrophages in 23-week old Mist1-Kras
G12D 
pancreata (Figure 1C-D). These data indicate that 
the Mist1-Kras
G12D
 mouse pancreatic tumor model is a valid system for us to study the role of 
pancreatic CAFs in tumor initiation and development.  
Smo is Efficiently Deleted in Pancreatic Cancer Associated Fibroblasts 
In order to conditionally delete Smo in pancreatic fibroblasts in the Mist-Kras
G12D 
pancreatic 









 control mice. Using a novel procedure for harvesting pancreatic fibroblasts 
(Figure 2A), we were able to isolate over 99% pure populations of fibroblasts as measured by the 
expression of fibroblast marker SMA and lack of expression of epithelial marker cytokeratin 19 
(Figure 2B). Furthermore, we showed that these cells also expressed alternative fibroblast marker 
vimentin and lacked expression of cytokeratin 8 (data not shown). After verifying that novel 
method of purifying fibroblasts was effective, we showed that Smo was deleted exclusively in 




 mice by western blot analysis 
(Figure 2C). In order to show that the Smo was also excised in vivo, we stained formalin fixed 









 mice (Figure 2D). Collectively, this data shows that we can 
generate pure populations of murine pancreatic CAFs and that Smo
fl





 mice, leading to decreased SMO protein. 
Loss of Smo in Pancreatic Cancer Associated Fibroblasts Increases Premalignant Lesions in 
the Mist1-Kras
G12D
 Murine Pancreatic Tumor Initiation Model. 
In order to show the effect of Smo loss in pancreatic fibroblasts on tumorigenesis events, we 














 mice have significantly increased acinar-to-ductal metaplastic (ADM) 
lesions as measured by ducts that are double positive for epithelial cell marker cytokeratin 19 
(CK19) as well as acinar cell marker amylase (Figure 3A).  Additional histological analysis 
showed that mice lacking Smo in pancreatic CAFs have enhanced onset of Pancreatic 
Intraepithelial Neoplastic (PanIN) lesions relative to Smo-intact age-matched controls (Figure 
3B).  In order to explain the increase in premalignant lesions, we stained pancreatic sections for 
the fibroblast marker smooth muscle actin (SMA) and the cellular proliferation marker Ki67 and 
showed that Smo fibroblast deleted mice had increased percentage of proliferating ductal cells 
(Figure 3C). Thus, these results indicate that fibroblast specific deletion of Smo in the pancreas 
leads to a significant acceleration in premalignant PanIN and ADM lesion formation due to an 
increase in the proliferation potential of the pancreatic epithelium. 
Smo Deletion Leads to Loss of PTEN in Pancreatic Cancer Associated Fibroblasts 
To understand how deleting Smo may change the proliferation potential of the adjacent tumor 









pancreata and performed microarray (Figure 4A). Gene expression analysis followed by Gene 
Set Enrichment Analysis (GSEA) determined that Smo deletion significantly altered the PI3K 
pathway within fibroblasts (Figure 4B). Heatmaps depicting to top up- and down-regualted genes 
in each genotype are shown (Figure 4C). Altered PI3K signaling in KCS fibroblasts was 
validated by Western blot analysis showing increased phosphorylation of AKT at Serine-473 
(Figure 4D). Because AKT signaling was activated, we also analyzed the expression of the 
PTEN tumor suppressor, a key negative regulator of this pathway. PTEN protein levels were 
significantly decreased in Smo-deleted fibroblasts (Figure 4D). 
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